Yu Xun, Zhang Lemeng, Chen Jianhua
Department of Thoracic Medicine, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.
Department of Thoracic Medicine, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 283 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, P.R. China.
Open Med (Wars). 2018 Apr 19;13:142-147. doi: 10.1515/med-2018-0022. eCollection 2018.
This study investigated the clinical efficacy, safety and tolerance of endostatin combined with gemcitabine and carboplatin for patients with advanced nonsmall cell lung cancer (NSCLC). From January 2010 to January 2014, 49 patients with advanced NSCLC were retrospectively evaluated; we defined 2 subgroups: a combination group (chemotherapy + anti-angiogenic therapy) and a chemotherapy group (chemotherapy only). The cases in the chemotherapy group received treatment with gemcitabine and carboplatin only, whereas the cases in the combination group received endostatin in combination with gemcitabine and carboplatin. The patients received 2 cycles of treatment (21 days/cycle). The clinical efficacy and adverse events were observed and compared. The disease control rate in the combination group was significantly higher compared with the chemotherapy group (P < 0.05). When comparing the cases of squamous carcinoma, the disease control rate in the combination group was significantly higher than the chemotherapy group (P < 0.05). Moreover, the progression free survival in the combination group was higher than that for the chemotherapy group, with a statistically significant difference (P < 0.05). The combination of endostatin with chemotherapeutic agents is improve to the survival of patients with advanced NSCLC favorably; the adverse events of this regimen are well tolerated.
本研究调查了内皮抑素联合吉西他滨和顺铂治疗晚期非小细胞肺癌（NSCLC）患者的临床疗效、安全性及耐受性。2010年1月至2014年1月，对49例晚期NSCLC患者进行回顾性评估；我们将患者分为2个亚组：联合治疗组（化疗+抗血管生成治疗）和化疗组（单纯化疗）。化疗组患者仅接受吉西他滨和顺铂治疗，而联合治疗组患者接受内皮抑素联合吉西他滨和顺铂治疗。患者接受2个周期的治疗（21天/周期）。观察并比较临床疗效及不良事件。联合治疗组的疾病控制率显著高于化疗组（P<0.05）。比较鳞癌病例时，联合治疗组的疾病控制率显著高于化疗组（P<0.05）。此外，联合治疗组的无进展生存期高于化疗组，差异有统计学意义（P<0.05）。内皮抑素与化疗药物联合使用有利于改善晚期NSCLC患者的生存；该治疗方案的不良事件耐受性良好。
